These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 14663298

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease.
    Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR.
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2902-8. PubMed ID: 24092750
    [Abstract] [Full Text] [Related]

  • 23. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
    Bilgen D, Sönmez H, Ekmekçi H, Ulutin T, Oztürk Z, Kökoğlu E, Bayram C, Soner A, Domaniç N.
    Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients.
    Marcucci R, Brunelli T, Fedi S, Pepe G, Giusti B, Gori AM, Prisco D, Falai M, Margheri M, Abbate R, Gensini GF.
    Eur J Clin Invest; 2005 Jan; 35(1):1-7. PubMed ID: 15638812
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The importance of Lp(a)-fibronectin interaction in atherogenesis.
    Sönmez H, Süer S, Kökoğlu E, Dirican A, Ulutin T, Uçişik N, Ulutin ON.
    Haematologia (Budap); 1997 Jan; 28(3):149-53. PubMed ID: 9283915
    [Abstract] [Full Text] [Related]

  • 28. [Association between lipoprotein(a) and coronary disease].
    Bovet P, Burnand B, Kappenberger L, Riesen W, Darioli R.
    Schweiz Med Wochenschr; 1993 Nov 13; 123(45):2138-46. PubMed ID: 8266034
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Lipoprotein(a), fibrinogen and vascular mortality in an elderly northern Italian population.
    D'Angelo A, Ruotolo G, Garancini P, Sampietro F, Mazzola G, Calori G.
    Haematologica; 2006 Dec 13; 91(12):1613-20. PubMed ID: 17145597
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Physical activity, coronary heart disease, and inflammatory response.
    Rothenbacher D, Hoffmeister A, Brenner H, Koenig W.
    Arch Intern Med; 2003 May 26; 163(10):1200-5. PubMed ID: 12767957
    [Abstract] [Full Text] [Related]

  • 33. Plasma fluorescent oxidation products: independent predictors of coronary heart disease in men.
    Wu T, Rifai N, Willett WC, Rimm EB.
    Am J Epidemiol; 2007 Sep 01; 166(5):544-51. PubMed ID: 17615090
    [Abstract] [Full Text] [Related]

  • 34. Lipoprotein(a) in South Indian type 2 diabetic subjects in relation to diabetic vascular complications.
    Deepa R, Mohan A, Rema M, Haranath SP, Saravanan G, Mohan V.
    J Assoc Physicians India; 2002 May 01; 50(5):657-61. PubMed ID: 12186119
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects.
    Emanuele E, Peros E, Minoretti P, Falcone C, D'Angelo A, Montagna L, Geroldi D.
    BMC Cardiovasc Disord; 2003 Dec 12; 3():12. PubMed ID: 14670093
    [Abstract] [Full Text] [Related]

  • 37. Association between plasma homocysteine levels and coronary artery disease: a population-based study in northern Greece.
    Boufidou AI, Makedou AD, Adamidis DN, Karvounis HI, Gourassas JT, Kesidis HT, Makedou KG, Papadopoulos CE, Parharidis GE, Louridas GE.
    Curr Med Res Opin; 2004 Dec 12; 20(2):175-80. PubMed ID: 15006011
    [Abstract] [Full Text] [Related]

  • 38. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study.
    Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brümmer J, Gutzki FM, Berger J, Frölich JC, Böger RH.
    Circulation; 2004 Feb 24; 109(7):843-8. PubMed ID: 14757688
    [Abstract] [Full Text] [Related]

  • 39. The effect of high-dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease.
    Bostom AG, Hume AL, Eaton CB, Laurino JP, Yanek LR, Regan MS, McQuade WH, Craig WY, Perrone G, Jacques PF.
    Pharmacotherapy; 1995 Feb 24; 15(4):458-64. PubMed ID: 7479198
    [Abstract] [Full Text] [Related]

  • 40. Lipoprotein (a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions.
    Zorio E, Falco C, Arnau MA, España F, Osa A, Ramon LA, Castello R, Almenar L, Palencia MA, Estelles A.
    Haematologica; 2006 Apr 24; 91(4):562-5. PubMed ID: 16585023
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.